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Introduction
Cystic fibrosis (CF) is a chronic, inherited disorder that 
affects the respiratory tract, pancreas, gastrointestinal 
system, exocrine sweat glands, and genital tract. In 
its classic form, CF involves the accumulation of thick 
mucus secretions that obstruct the respiratory tract and 
exocrine glands.1 The condition is inherited in an autosomal 
recessive manner. It is caused by mutations in the cystic 
fibrosis transmembrane regulator (CFTR) gene.2 It is most 
common amongst individuals of north-west European 
descent, but has been described in almost every ethnic 
group.3 In South Africa, carrier frequencies for CF have been 
estimated as 1 in 20 for the white population, 1 in 55 for the 
coloured population, and approximately 1 in 34 for the black 
population.4,5 However, further studies are required to verify 
the frequency for the latter group. The Molecular Genetics 
Laboratory of the Division of Human Genetics, School of 
Pathology, University of the Witwatersrand and the National 
Health Laboratory Service (NHLS), Johannesburg, perform 
a large portion of the country’s CF genetic testing, and 
started offering testing to all patients with CF and their family 
members, soon after the CFTR gene was cloned in 1989.2 
At present, this laboratory tests for 30 common CF-causing 
mutations in individuals from the white, coloured and 
Indian populations, and one common mutation in the black 
population. The state covers the costs of genetic testing 
for patients at state hospitals. Testing costs for private 
patients are either covered by their medical aid schemes, or 
themselves. As more than 1 900 CF-causing mutations have 
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been identified worldwide, full CFTR mutation screening is 
not practical.6 Thus, testing for the most common mutations 
in each population is used. Therefore, it is important to know 
the patient’s ethnicity. 
Parents of an affected individual are obligate carriers, but 
many relatives, including aunts, uncles, cousins and healthy 
siblings of probands (affected individuals), are also at risk 
of being carriers. Healthy unaffected siblings are at the 
highest risk (67%). Genetic counselling serves an important 
role in educating such individuals about the condition, their 
genetic risks, and the available testing options, as well as 
providing psychosocial support to families, and facilitating 
testing and feedback.7 
Since 1975, the genetic counsellors and medical geneticists 
of the Division of Human Genetics, School of Pathology, 
University of the Witwatersrand, and the NHLS, have 
been offering genetic counselling to individuals with CF 
and their families in general genetic counselling clinics. 
Referrals originated from doctors treating affected patients 
in and around Johannesburg, in both the state and private 
hospital sectors. However, at the beginning of 2006, a new 
specialist genetic counselling clinic was established within 
the paediatric and adult CF clinics at Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH). Over the years, 
the nature of the genetic counselling service has remained 
the same. However, with time, more trained individuals have 
become available to see patients, allowing us to allocate a 
dedicated staff member to the CF clinics at CMJAH. 
In South Africa, genetic counselling for CF has not been the 
subject of much research. Therefore, the aim of the present 
study was to gain information on following topics: the 
uptake of genetic counselling services and mutation testing 
by families with a member with CF, the number of at-risk 
relatives per family needing such services, and the impact 
of introducing a new service at the CMJAH CF clinics on 
affected families. 
Background 
The present study was descriptive and retrospective. 
Ethics approval for the study was granted by the Human 
Research Ethics Committee (Medical) of the University of 
the Witwatersrand (reference number: M060943).
The sample included all individuals from families with a 
member with CF, and those who were confirmed CF carriers, 
counselled at the genetic counselling clinics of the Division 
of Human Genetics, University of the Witwatersrand and the 
NHLS, Johannesburg, from the beginning of 1990 until the 
end of 2006. 
A total of 170 records with the diagnosis of CF were 
available for this 17-year period. Altogether 153 out of 
170 (90%) files were located. Of the 153 families, 13 (8%) 
were related to other families in the series, and 140 (92%) 
were unrelated. Where families were related to each other, 
information pertaining to the number of at-risk relatives, 
as well as those who had undergone CF mutation testing, 
was recorded once only per extended family during data 
collection.
Method
Information was gathered from the 153 files, and entered 
onto specifically constructed data collection sheets. 
Counsellees were only included in the analysis if they were 
12 years of age, or older. In general, each file contained 
the personal details of the counsellees, a family pedigree, 
molecular genetics reports, notes made by the genetic 
counsellor or medical geneticist regarding the counselling 
session, and a copy of the comprehensive case summary 
written to the referring doctor. 
Particulars collected on each family included the number 
of counsellees present at an initial genetic counselling 
session, their relationships to the proband (e.g. CF probands 
themselves, parents, or specific relative, or partner of 
proband), their ages, and ethnic group. Information gathered 
pertaining to the counselling session included the session 
venue, the reasons for attendance, the referring person, 
and number of follow-up consultations. Pedigree analysis 
involved assessing whether consanguinity was present, and 
determining the number of at-risk relatives. At-risk relatives 
were defined as blood relatives of a proband, each of whom 
had a minimum carrier risk of 1 in 4 (25%). Individuals with 
lower risks were not included, and any individuals who were 
associated with a proband through marriage or adoption, 
were also excluded. 
Although biological parents of probands are obligate carriers 
for CF mutations (100% risk), they too were included in the 
at-risk relatives group. Grandparents, who are at 50% risk 
of carrying a CF-causing mutation, were excluded from this 
study in order to focus on the generations for whom carrier 
status would have reproductive implications. Data were also 
collected on family members who had pursued CF mutation 
analysis, and on their test results.
The data were divided into those obtained for the years 
prior to 2006, i.e. 1990-2005, and those for 2006. Although 
it may not be ideal to compare data collected over a period 
of 16 years, to data collected over only one year, these two 
time periods were used in order to assess the impact of 
introducing the genetic counselling service in 2006 at the 
CMJAH CF clinics.
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Most of the data generated were quantitative, and 
expressed as frequencies. Means and standard deviations 
were calculated using the statistical analysis functions in 
the Microsoft Office Excel computer programme. The chi-
square test was used to calculate p-values, and these were 
considered significant if they were < 0.05.
Results
A total of 271 individuals from the 153 families, attended an 
initial genetic counselling session over the 17-year period. 
Among the 271 counsellees, there were significantly more 
females (157, 58%) than males (114, 42%): p-value < 0.009. 
Ninety-five families received genetic counselling from 1990-
2005, averaging six families per year, (range two to 13), and 
a further 58 families were counselled during 2006 alone. 
The age of the counsellees ranged from 12-66 years, with a 
mean of 30 years. Consanguinity was present in five (4%) of 
the 140 families. The clinic venue where these families were 
counselled changed three times over the years. However, 
in 2006, 90% (52 out of 58) of all CF genetic counselling 
sessions took place at CMJAH CF clinics.
The majority (93%) of counsellees were from the white 
population (Table I). However, the small numbers from the 
black and coloured populations doubled in 2006, compared 
to the numbers over the previous 16 years.
The data for the counsellees using the service were analysed 
in terms of whether they were the proband, or related to the 
proband (Figure 1). The largest single group of counsellees 
were parents of CF probands (93 out of 271, 35%), followed 
by unrelated individuals (74 out of 271, 27%), and then 
the probands (44 out of 271, 16%). In almost all cases, an 
“unrelated individual” was the partner of a blood relative to 
a proband. Only a small number of siblings (18 out of 271, 
7%) sought genetic counselling. 
Over half of the referrals originated from medical specialists 
(86 out of 153, 56%), particularly paediatricians (49 out of 
86, 57%) and physicians (10 out of 86, 12%). The remainder 
of referrals derived from the CF probands (28 out of 153, 
18%) themselves and other individuals, such as nurses (20 
out of 153, 13%), general practitioners (15 out of 153, 10%), 
and relatives of affected individuals (4 out of 153, 3%). 
Specialist referrals increased considerably during 2006 
(a total of 41 out of 58, 71% referrals), compared to the 
previous 16 years (a total of 45 out of 95, 47%, mean of 2.8 
referrals per year). 
The reasons why counsellees attended their first genetic 
counselling session are given in Table II, and the numbers 
for 1990-2005 are compared with those for 2006. In one 
case, noted in Table II, the family had CF carrier testing 
performed by a private laboratory without prior genetic 
counselling, and they sought genetic counselling to have 
their results explained to them.





n (%) n (%) n (%) 
Information gathering 45 (47) 56 (97) 101 (66)
Prenatal counselling 35 (37) 2 (3) 37 (24)
Planning a family 14 (15) 0 (0) 14 (9)
Result-giving session 1 (1) 0 (0) 1 (1)
Total 95 (100) 58 (100) 153 (100)
Approximately half of the follow-up genetic counselling 
sessions involved result-giving (20 out of 41, 49%). The 
number of follow-up sessions increased greatly during 
2006. A total of 41 follow-up sessions took place over the 
17-year period, 29 (71%) of which occurred during 2006. 
Examination of the pedigrees of the 140 unrelated families 
showed that there were 1 991 relatives with a carrier risk of 
25% or more (Table III). Exclusion of the obligate carriers 
(n = 271), resulted in a sub-total of 1 720 at-risk relatives 








































* Unrelated individuals were partners or spouses of blood relatives to probands
Figure 1: Relationship of counsellees to probands (n = 271) attending 
clinics for genetic counselling
Table I: Ethnicity of individuals attending genetic counselling sessions for 
cystic fibrosis from 1990-2005, and in 2006
Ethnicity
Number and percentages of counsellees
1990-2005  2006 Total
n (%) n (%) n (%) 
White 170 (97) 83 (88) 253 (93)
Black 2 (1) 5 (5) 7 (3)
Coloured 2 (1) 6 (6) 8 (3)
Indian 2 (1) 1 (1) 3 (1)
Total 176 (100) 95 (100) 271 (100)
Original Research: Uptake of genetic counselling services by patients with cystic fibrosis and their families
253 Vol 54 No 3S Afr Fam Pract 2012
potential carriers per family. Of these, 1 720 at-risk relatives, 
118 (7%) were known to have undergone CF mutation 
testing through the NHLS, and 73 out of 118 (62%) were 
found to be carriers. Individuals at higher risk were more 
likely to be tested. 
According to the counselling records and analysis of the 
pedigrees, a total of 168 out of 1 991 at-risk relatives, 
including obligate carriers, presented for genetic 
counselling. Therefore, eight per cent of relatives with a 
carrier risk of 25% or higher, received genetic counselling 
within our service.
Discussion
The largest single group of individuals who attended genetic 
counselling clinics were parents of children with CF. This 
finding is expected, as parents of affected children are 
most in need of psychosocial support, an understanding 
about recurrence risks and their prenatal testing options, 
medical and genetic information, and referral to appropriate 
services. 
According to our findings, the majority of counsellees 
were in their thirties, and were from the white population. 
Considering that most individuals who are known to have 
CF are from populations of European extraction, and that 
the prevalence of CF is highest in these populations, this 
finding is not unexpected.4 However, it was necessary to 
analyse the data by ethnic group because a carrier frequency 
of 1 in 34 has been estimated for the South African black 
population.5 Therefore, one would expect that a substantial 
number of affected black families would be referred. In this 
study, although only 3% of all counsellees were from the 
black population, there was an increase in referrals from 
this group once hospital-based genetic counselling clinics 
were set up in 2006. Given the fact that the specific CF-
causing mutation in the South African black population has 
only been known since 1996, and that CF was previously 
considered to be rare in this ethnic group, it is likely that 
CF is still under-recognised and under-diagnosed in black 
children.8 There is a need for medical practitioners to 
consider this diagnosis in black patients, and refer them 
for genetic counselling. Furthermore, mutation detection 
in affected individuals from the black, coloured and Indian 
populations is often problematic. Only a few mutations have 
been identified in these populations, and other common 
mutations have not yet been investigated.
CF probands were the third largest group to attend genetic 
counselling. This is encouraging, as a previous study showed 
that half of South African CF probands were unaware of the 
inheritance pattern of their disorder.9 This finding suggests 
that the in-hospital service may be effective in meeting 
the needs of the CF probands and their parents. It also 
indicates that as a result of improved medical treatment, CF 
probands are living through to, and beyond, adolescence, 
and planning relationships and families.
A finding that caused concern was the small proportion (22%) 
of siblings and extended family members, at significant risk 
of being carriers, who sought genetic counselling sessions 
(Figure 1). With respect to healthy siblings (at 67% risk), one 
would expect more than the seven per cent (Figure 1), found 
here, to have attended a genetic counselling consultation. 
Interestingly, 39% (Table III) had undergone genetic testing, 
mostly without expert genetic counselling. This finding 
echoes the lack of knowledge amongst siblings of CF 
probands regarding the condition and its inheritance, as 
reported by Henley and Hill.9 Another South African study 
found that the lack of knowledge among unaffected siblings 
could also be associated with the guilt expressed by 
parents who realised they may have passed on the affected 
gene to their normal children, and who may therefore have 
found it difficult to discuss this matter with them.10 The 
low uptake of genetic counselling by non-nuclear family 
members may be due to the fact that CF is often viewed 
as a nuclear family problem, which does not necessarily 
encompass the extended family.11 In addition, it has been 
reported that the main reason why people do not present 
for genetic counselling is because they are not aware of 
Table III: At-risk individuals, with carrier risks of 25-100%, in 140 unrelated families, and the results of those tested
Carrier risk
(%)
Total number of  
at-risk individuals
At-risk individuals tested Tested individuals found to 
be carriers
Tested individuals found to 
be affected
n n (%) n (%) n (%)
100 271 99 (37) 86 (87) 0 (0)
67 123 48 (39) 35 (73) 1 (2)*
50 662 53 (8) 29 (55) 3 (6)**
33 53 2 (4) 1 (50) 0 (0)
25 882 15 (2) 8 (53) 0 (0)
Total 1991 217 159 4
*One sibling, supposedly unaffected, but found to have two mutations (phenotypic variability between affected individuals)
**Foetuses diagnosed by prenatal testing
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its existence.12 They may not have been informed of their 
risk status, the related implications, and how a genetic 
counselling session would benefit them. Primary health care 
personnel, such as general practitioners and nurses, may 
have the best opportunities to promote referral to genetic 
counselling clinics. With only 10% of genetic counselling 
referrals originating from general practitioners, it is essential 
that the awareness of the genetic counselling service is 
promoted among these doctors. General practitioners are 
often the key clinicians involved in the overall management 
and care of the affected individual, and also the rest of the 
family. 
“Information gathering” was the reason why half the 
individuals attended genetic counselling over the 17-year 
period. This is in keeping with the findings of Veach et al.13 
This suggests that even where a diagnosis of CF has been 
known for many years, families have a specific need to 
understand the genetic component of the condition. This 
need should be met by genetic counsellors and medical 
geneticists. It is unlikely that treating physicians will provide 
genetic counselling themselves. This is supported by our 
finding that most counsellees attended a genetic counselling 
session to obtain more information about their condition, 
which had obviously not previously been communicated 
to them in a manner that they could understand. Many 
patients said they were grateful for the information as they 
had not received a formal genetic explanation from their 
treating doctors. 
Our findings show that when a genetic counselling service 
is incorporated into the hospital-based clinical care of 
CF patients, the uptake increases. Collins et al also 
found that, through the integration of the genetic service 
into the care programme, uptake was more likely to be 
favourable.12 When genetic counselling is available within 
the clinic where an individual is being treated, utilisation of 
the service is far greater than when it is offered elsewhere, 
and requires referral, and the attendance of patients at 
another venue. Convenience, low costs, and familiarity with 
the clinic and its staff are positive factors associated with 
the incorporation of the genetic counselling service into 
treatment clinics. In addition, the large numbers of follow-
up sessions, and the increase in attendance of those from 
ethnic groups other than white, which occurred in 2006, 
reflects the usefulness of having the genetic service readily 
available and accessible.
Each family in this study had an average of 14 at-risk 
relatives, in keeping with a previous study that found 15 
at-risk relatives per family.14 However, only 8% (168 out of 
1 991) of all such relatives attended genetic counselling. 
Since no other genetic counselling service is available in 
Johannesburg at the time of this study, it is unlikely that they 
received expert genetic counselling elsewhere, regardless 
of whether or not they were private or state hospital sector 
patients. Furthermore, only a small group (7%) of at-risk 
relatives, excluding obligate carriers, used the available CF 
mutation testing facilities.
In this study, the under-utilisation of the genetic counselling 
service by at-risk relatives requires consideration. It may 
result from lack of communication among family members, 
or be due to inaccurate carrier perceptions among relatives. 
According to the World Health Organization (WHO), it is 
the ethical duty of an individual who is aware of a genetic 
condition in his or her family to inform other blood relatives 
that they may be at genetic risk.15 The WHO does not 
recommend that genetic professionals make direct contact 
with the relatives, but rather that they act as mediators, by 
instilling a feeling of duty and responsibility in the counsellees 
towards relatives.15 South African genetic counsellors and 
medical geneticists follow this protocol. The use of an 
appropriate information letter or pamphlet addressed to the 
at-risk relatives, and given to counsellees at clinics to pass 
on to their relatives, motivating and inviting them to attend 
a genetic counselling session, would hopefully increase 
awareness among family members. 
Other reasons influencing the decision to determine one’s 
genetic status may relate to the fact that knowledge of 
carrier status can potentially threaten one’s self-concept, 
as stated by some researchers.16 It is possible that some 
at-risk relatives chose not to pursue carrier testing due 
to fear of a positive result, leading to social harm and 
discrimination, particularly with regard to loss of insurance 
or employment.17 They may also have been ignorant about 
their genetic risks. Of all the non-obligate at-risk relatives 
who were tested in the present study, 62% (73 out of 118) 
were CF carriers (Table III). These positive test results raise 
concern about the large number of untested at-risk relatives 
who are unaware of their genetic status. If they marry, or 
are in a relationship with, a CF carrier, they are at-risk of 
having children with CF. Therefore, it is essential for medical 
practitioners and other health professionals to encourage 
cascade testing within families who are affected by CF.
Conclusion
Based on the results of the current study, the 2006 
introduction of the genetic counselling service at the CMJAH 
CF clinics has been worthwhile. The number of referrals, 
uptake of counselling sessions and follow-up consultations, 
increased considerably during that year, compared to 
previous years. The results pinpoint an obvious lack in 
referrals from general practitioners and family members of 
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affected individuals. This may be due to poor promotion of 
the genetic counselling service and its benefits. Genetic 
counselling is an essential part of the diagnosis and care of 
any genetic disorder. This study highlights the benefits and 
value of the service, particularly within the specialist clinics, 
and will hopefully result in ongoing appropriate referrals 
from healthcare professionals and the general public. In 
addition, through increased interaction and involvement 
with other health professionals at treatment clinics, genetic 
counsellors and medical geneticists will hopefully become 
accepted and established members of the multidisciplinary 
team caring for patients with genetic conditions. 
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